Featured NewsNovo Nordisk reveals obesity drug with up to 22 percent weight lossmanamalive.comJanuary 24, 2025January 24, 2025 by manamalive.comJanuary 24, 2025January 24, 20250164 Novo Nordisk’s amycretin shows up to 22% weight loss in trials, boosting its stock by 6.87% as the drug exhibits safety and potential as a next-gen obesity treatment....
